{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:10:46Z","timestamp":1760004646570,"version":"build-2065373602"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jpba.2023.115772","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T12:36:47Z","timestamp":1696509407000},"page":"115772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Challenges with retention and recovery of impurities containing acidic moieties during analytical UHPLC method development and validation for gefapixant freebase"],"prefix":"10.1016","volume":"237","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6865-9221","authenticated-orcid":false,"given":"Holst","family":"Halsey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jackson","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6374-4689","authenticated-orcid":false,"given":"Chunli","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya","family":"Parganiha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siqing","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Duran-Capece","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Fett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shilpa","family":"Mathkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6763-189X","authenticated-orcid":false,"given":"Sachin","family":"Lohani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jpba.2023.115772_bib1","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1021\/acs.oprd.0c00248","article-title":"Development of a green and sustainable manufacturing process for gefapixant citrate (MK-7264) part 1: introduction and process overview","volume":"24","author":"Ren","year":"2020","journal-title":"Org. Process Res. Dev."},{"issue":"11","key":"10.1016\/j.jpba.2023.115772_bib2","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1021\/acs.oprd.0c00247","article-title":"Development of a green and sustainable manufacturing process for gefapixant citrate (MK-7264). Part 5: completion of the API free base via a direct chlorosulfonylation process","volume":"24","author":"Di Maso","year":"2020","journal-title":"Org. Process Res. Dev."},{"issue":"1","key":"10.1016\/j.jpba.2023.115772_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9673(00)00811-6","article-title":"Optimisation and characterisation of silica-based reversed-phase liquid chromatographic systems for the analysis of basic pharmaceuticals","volume":"897","author":"Vervoort","year":"2000","journal-title":"J. Chromatogr. A"},{"issue":"1","key":"10.1016\/j.jpba.2023.115772_bib4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.chroma.2004.11.096","article-title":"The combined effect of silanols and the reversed-phase ligand on the retention of positively charged analytes","volume":"1063","author":"Neue","year":"2005","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2023.115772_bib5","unstructured":"P.C. Iraneta, K.D. Wyndham, D.R. McCabe, T.H. Walter, Charged surface hybrid (CSH) technology and its use in liquid chromatography [White paper]. Retrieved July 6, 2022, from Waters Corp: https:\/\/www.waters.com\/webassets\/cms\/library\/docs\/720003929en.pdf, (2011)."},{"key":"10.1016\/j.jpba.2023.115772_bib6","article-title":"Method for evaluation of ionic interactions in liquid chromatography","volume":"2020","author":"Kadlecov\u00e1","year":"1625","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2023.115772_bib7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.chroma.2013.01.063","article-title":"Effect of the pH and the ionic strength on overloaded band profiles of weak bases onto neutral and charged surface hybrid stationary phases in reversed-phase liquid chromatography","volume":"1282","author":"Gritti","year":"2013","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2023.115772_bib8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.chroma.2012.02.027","article-title":"A comparison of overload behaviour for some sub 2\u03bcm totally porous and sub 3\u03bcm shell particle columns with ionised solutes","volume":"1235","author":"Fallas","year":"2012","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2023.115772_bib9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.chroma.2013.01.027","article-title":"Effect of the ionic strength on the adsorption process of an ionic surfactant onto a C18-bonded charged surface hybrid stationary phase at low pH","volume":"1282","author":"Gritti","year":"2013","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2023.115772_bib10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.chroma.2013.01.024","article-title":"Adsorption behaviors of neutral and ionizable compounds on hybrid stationary phases in the absence (BEH-C18) and the presence (CSH-C18) of immobile surface charges","volume":"1282","author":"Gritti","year":"2013","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2023.115772_bib11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.talanta.2012.01.054","article-title":"Evaluation of new mixed-mode UHPLC stationary phases and the importance of stationary phase choice when using low ionic-strength mobile phase additives","volume":"93","author":"Nov\u00e1kov\u00e1","year":"2012","journal-title":"Talanta"},{"issue":"14","key":"10.1016\/j.jpba.2023.115772_bib12","doi-asserted-by":"crossref","first-page":"6936","DOI":"10.1021\/ac401481z","article-title":"High-resolution peptide mapping separations with MS-friendly mobile phases and charge-surface-modified C18","volume":"85","author":"Lauber","year":"2013","journal-title":"Anal. Chem."},{"issue":"17","key":"10.1016\/j.jpba.2023.115772_bib13","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s10337-014-2633-9","article-title":"Robust UHPLC separation method development for multi-API product containing amlodipine and bisoprolol: the impact of column selection","volume":"77","author":"Korm\u00e1ny","year":"2014","journal-title":"Chromatographia"},{"issue":"5","key":"10.1016\/j.jpba.2023.115772_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.5062","article-title":"Quality by design with design of experiments approach for development of a stability-indicating LC method for enzalutamide and its impurities in soft gel dosage formulation","volume":"35","author":"Katakam","year":"2021","journal-title":"Biomed. Chromatogr."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523005411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523005411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:31:37Z","timestamp":1760002297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708523005411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":14,"alternative-id":["S0731708523005411"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115772","relation":{},"ISSN":["0731-7085"],"issn-type":[{"type":"print","value":"0731-7085"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges with retention and recovery of impurities containing acidic moieties during analytical UHPLC method development and validation for gefapixant freebase","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115772","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115772"}}